JPMorgan CEO Jamie Dimon might finally be ready to retire; Here's what we know about his successor and possible post-banking career

Jamie Dimon, CEO of JPMorgan, has announced that the bank is "well on its way" to finding his successor after months of speculation about his retirement. Despite his previous jokes about being five years away from retirement, Dimon, who is 68, now admits that the timeframe for his succession plan has shortened. With JPMorgan's growth in areas like investment banking, AI, and tech spending, Dimon's legacy has grown the bank into the largest US bank by assets under his leadership.

The bank has been preparing for his departure and speculations are rife about his possible post-banking career, with politics being a likely option.

Meanwhile, in other news:

  • Microsoft unveiled its Copilot+ PCs, which start at $999 and are powered by AI.
  • Neuralink is making some changes to its next implant procedure, embedding the wires deeper into the brain to fix problems encountered with its first patient.
  • OpenAI has angered Scarlett Johansson after it released a voice for its new model that sounded "eerily similar" to hers.
  • Red Lobster has filed for Chapter 11 bankruptcy, saying it will continue to operate its restaurants for now.
  • A former Iranian official has partly blamed US sanctions for the helicopter crash that killed its president.
  • Donald Trump is considering a second presidential run in 2024.
  • Hims & Hers is entering the weight-loss drug market with injectables starting at $200 a month.
  • Bill Gates thinks you should read a new book to get smarter about how AI will transform education.
  • And Khaby Lame, the world's most-followed TikToker, built his business and where he's headed next.

Read more

Prospective observational study of peripheral intravenous cannula utilisation and frequency of intravenous fluid delivery in the emergency department: convenience or necessity?

Introduction Over one billion peripheral intravenous cannulas (PIVCs) are inserted worldwide each year. Insertion of PIVCs is associated with pain, phlebitis, occlusion, and medication extravasation as well as the risk of catheter-associated infection, with an associated cost to departmental resources. Previous studies have not assessed if intravenous (IV) fluid delivery